Mutation and association analysis of the DAP-1 gene with schizophrenia

Psychiatry and Clinical Neurosciences

Volumn 57, Issue 5, 2003, Pages 545-547

  Aoyama, Shinsuke ^a   Shirakawa, Osamu ^a   Ono, Hisae ^a   Hashimoto, Takeshi ^a   Kajimoto, Yasuo ^a   Maeda, Kiyoshi ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Association study; DAP 1 gene; Direct sequencing; NMDA receptor; Polymorphism; Schizophrenia

Indexed keywords

ADENINE; CELL PROTEIN; DROSOPHILA DISCS LARGE PROTEIN; GLUTAMIC ACID; GUANINE; INSECT PROTEIN; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; POSTSYNAPTIC DENSITY 95 ASSOCIATED PROTEIN 1; UNCLASSIFIED DRUG;

ADULT; AGED; AMINO ACID SEQUENCE; ARTICLE; CASE CONTROL STUDY; CHROMOSOME 18P; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE PREDISPOSITION; FEMALE; GENE IDENTIFICATION; GENE LOCATION; GENE MUTATION; GENE SEQUENCE; GENETIC MARKER; GENETIC SCREENING; GENETIC VARIABILITY; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; NUCLEOTIDE SEQUENCE; PATHOPHYSIOLOGY; POLYMERASE CHAIN REACTION; PROMOTER REGION; PROTEIN FUNCTION; SCHIZOPHRENIA; SEQUENCE HOMOLOGY; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM;

CASE-CONTROL STUDIES; DNA; DNA MUTATIONAL ANALYSIS; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MUTATION; NERVE TISSUE PROTEINS; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; SCHIZOPHRENIA;

EID: 0141962635     PISSN: 13231316     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1819.2003.01162.x     Document Type: Article

References (12)

1. Halberstadt AL. The phencyclidine-glutamate model of schizophrenia. Clin. Neuropharmacol. 1995; 18: 237-249.
2. Krystal JH, Karper LP, Seibyl JP et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in, humans: Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch. Gen. Psychiatry 1994; 51: 199-214.
3. Javitt DC, Zylberman I, Zukin SR, Heresco-Levy U, Linden-mayer J. Amelioration of negative symptoms in schizophrenia by glycine. Am. J. Psychiatry 1994; 151: 1234-1236.
4. Van Berckel BNM, Hijman R, van der Linden JA, Westenberg HGM, van Ree JM, Kahn RS. Efficacy and tolerance of D-cycloserine in drug-free schizophrenic patients. Biol. Psychiatry 1996; 40: 1298-1300.
5. Satoh K, Yanai H, Senda T et al. DAP-1, a novel protein that interacts with the guanylate kinase-like domains of hDLG and PSD-95. Genes Cells 1997; 2: 415-424.
6. Takeuchi M, Hata Y, Hirao K, Toyoda A, Irie M, Takai Y. SAPAPs: A family of PSD-95/SAP90-associated proteins localized at postsynaptic density. J. Biol. Chem. 1997; 272: 11 943-11 951.
7. Kajimoto Y, Shirakawa O, Lin X.-H. et al. Synapse-associated protien 90/postsynaptic density-95 -associated protein (SAPAP) is expressed differentially in phencyclidine-treated rats and is increased in the nucleus accumbens of patients with schizophrenia. Neuropsychopharmacology in press.
8. Scannevin RH, Huganir RL. Postsynaptic organization and regulation of excitatory synapses. Nat. Rev. 2000; 1: 133-141.
9. Berrettini W, Ferraro T, Goldin L et al. Chromosome 18 DNA markers and manic depressive illness: Evidence for a susceptibility gene. Proc. Natl Acad. Sci. USA 1994; 91: 5918-5921.
10. Schwab SG, Hallmayer J, Lerer B et aL Support for a chromosome 18p locus conferring susceptibility to functional psychoses in families with schizophrenia, by association and linkage analysis. Am. J. Hum. Genet. 1998; 63: 1139-1152.
11. Haga H, Yamada R, Ohnishi Y, Nakamura Y, Tanaka T. Gene-based SNP discovery as part of the Japanese Millennium Genome Project: Identification of 190562 genetic variations in the human genome. J. Hum. Genet. 2002; 47: 605-610.
12. Berrettini WH. Are schizophrenic and bipolar disorders related? A review of family and molecular studies. Biol. Psychiatry 2000; 48: 531-538.